PK Interaction of Erythromycin and Itraconazole on SAR443820 in Healthy Adults

Phase 1, open-label trial of oditrasertib in amyotrophic lateral sclerosis (ALS) (2 cohorts), sponsored by Sanofi. Primary endpoints: Area under the plasma concentration from time zero to the last concentration above the limit of quantification and Area under the plasma concentration. Started Feb 2022; status: completed.